Caption Management’s Pacira BioSciences PCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-53,844
Closed -$1.01M 1911
2024
Q4
$1.01M Buy
+53,844
New +$945K 0.01% 909
2024
Q2
Sell
-48,598
Closed -$1.38M 1420
2024
Q1
$1.42M Buy
48,598
+35,900
+283% +$1.1M 0.02% 645
2023
Q4
$428K Sell
12,698
-13,302
-51% -$389K 0.01% 996
2023
Q3
$798K Buy
26,000
+6,800
+35% +$245K 0.01% 832
2023
Q2
$769K Buy
+19,200
New +$794K 0.01% 728
2021
Q1
Sell
-10,833
Closed -$648K 1306
2020
Q4
$648K Buy
10,833
+833
+8% +$48.8K 0.01% 691
2020
Q3
$600K Buy
+10,000
New +$581K 0.01% 735

Other funds holding PCRX

Caption Management's PCRX Position: Q1 2025 in Review

Caption Management sold out of Pacira BioSciences (PCRX) in Q1 2025, closing a stake of 53,844 shares — an estimated $1.01M sold.

Caption Management first reported a position in PCRX in Q3 2020 and held it in 7 quarters. The position peaked at $1.42M in Q1 2024. 235 funds tracked by Wall St. Rank hold PCRX as of Q1 2025.

  • Caption Management reported no remaining Pacira BioSciences position as of Q1 2025 after selling out during the quarter.
  • Caption Management sold 53,844 Pacira BioSciences shares in Q1 2025, an estimated $1.01M.
  • Caption Management first reported a position in Pacira BioSciences in Q3 2020 and held it in 7 quarters.
  • Caption Management's Pacira BioSciences position peaked at $1.42M in Q1 2024.
  • 235 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2025.

Based on Caption Management's 13F filing for Q1 2025, filed 15 May 2025.